Preliminary But Maybe

New clinical trial designs and precision medicine may lead to new treatments for Alzheimer’s disease. Supported by FDA Commissioner Scott Gottlieb — preliminary results suggest that patients treated with the highest amounts of BAN2401 exhibited the greatest decline in amyloid plaques.

Source: https://www.genomeweb.com/scan/preliminary-maybe?utm_source=Sailthru&utm_medium=email&utm_campaign=Scan%20Fri%202018-07-27&utm_term=The%20Scan%20Bulletin